New drug combo aims to outsmart Hard-to-Treat lymphoma

NCT ID NCT04408638

Ongoing Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This phase 3 trial tests whether adding the immunotherapy glofitamab to standard chemotherapy (gemcitabine and oxaliplatin) works better than the usual rituximab-chemotherapy combo for people with diffuse large B-cell lymphoma that has come back or not responded to prior treatment. About 270 participants will be randomly assigned to one of the two treatment groups. The main goal is to see if the new combination helps people live longer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: glofitamab (a type of immunotherapy) combined with gemcitabine and oxaliplatin chemotherapy
What this could lead to: If successful, this could offer a new, more effective treatment option for people with hard-to-treat diffuse large B-cell lymphoma.
What could go wrong: This is a phase 3 trial, but results are not yet available. The new combination may not improve survival and could cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE LARGE B CELL LYMPHOMA

Contacts and locations

Show contact details

Locations

Aarhus Universitetshospital Skejby

Aarhus N, 8200, Denmark
Asan Medical Center

Seoul, 05505, South Korea
Baptist - MD Anderson Cancer Center

Jacksonville, Florida, 32207, United States
Beatson West of Scotland Cancer Centre

Glasgow, G12 OYN, United Kingdom
CHU Pontchaillou

Rennes, 35003, France
CHU de Liège (Sart Tilman)

Liège, 4000, Belgium
Centre Hospitalier Lyon Sud

Pierre-Bénite, 69495, France
Centrum Onkologii Ziemi Lubelskiej im. ?w. Jana z Dukli

Lublin, 20-090, Poland
Chang Gung Medical Foundation - Kaohsiung;Oncology

Kaoisung, 833, Taiwan
Chang Gung Medical Foundation - Linkou

Taoyuan, 333, Taiwan
Christie Hospital

Manchester, M20 4BX, United Kingdom
Chu de Montpellier-St Eloi

Montpellier, 34295, France
Community Cancer Institute (CCI)

Fresno, California, 93720, United States
Duke University Medical Center

Durham, North Carolina, 27705, United States
Fudan University Shanghai Cancer Center

Shanghai, 200120, China
Harbin Medical University Cancer Hospital

Harbin, 150081, China
Henan Cancer Hospital

Zhengzhou, 450008, China
Hopital Claude Huriez

Lille, 59037, France
Hopital Henri Mondor

Créteil, 94010, France
Hospital Clinico Universitario de Valencia

Valencia, 46010, Spain
Hospital Clínic i Provincial

Barcelona, 08036, Spain
Hospital Universitari Vall d'Hebron

Barcelona, 08035, Spain
Hospital Universitario Virgen del Rocio

Seville, 41013, Spain
Hospital Universitario la Paz

Madrid, 28046, Spain
Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States
Inselspital Bern, Insel-Gruppe AG

Bern, 3010, Switzerland
Institut Bergonie

Bordeaux, 33076, France
Instytut Hematologii i Transfuzjologii

Warsaw, 02-776, Poland
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Monash Health Monash Medical Centre

Clayton, Victoria, 3168, Australia
National Cancer Center

Goyang-si, 10408, South Korea
Nottingham City Hospital

Nottingham, NG5 1PB, United Kingdom
Oddzial Kliniczny Hematologii SPZOZ MSWiA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie

Olsztyn, 10-228, Poland
Peking University Third Hospital

Beijing, 100083, China
Peter Maccallum Cancer Centre

Melbourne, Victoria, 3000, Australia
Prince of Wales Hospital

Randwick, New South Wales, 2031, Australia
Pusan National University Hospital

Busan, 49241, South Korea
Rigshospitalet

København Ø, 2100, Denmark
Royal Adelaide Hospital

Adelaide, South Australia, 5000, Australia
Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08901, United States
Samsung Medical Center

Seoul, 06351, South Korea
Seoul National University Bundang Hospital

Seongnam-si, 13605, South Korea
Seoul National University Hospital

Seoul, 03080, South Korea
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Baltimore, Maryland, 21231, United States
Sir Charles Gairdner Hospital

Nedlands, Western Australia, 6009, Australia
St James's Institute of Oncology

Leeds, LS9 7TF, United Kingdom
St Vincent's Hospital Melbourne

Fitzroy, Victoria, 3065, Australia
Sun Yet-sen University Cancer Center

Guangzhou, 510060, China
Taichung Veterans General Hospital

Xitun Dist., 40705, Taiwan
Tianjin Cancer Hospital

Tianjin, 300060, China
UCLH - Clinical Trials Pharmacy B&D Centre

London, NW1 2PG, United Kingdom
UZ Leuven Gasthuisberg

Leuven, 3000, Belgium
Universitaetsklinikum Regensburg

Regensburg, 93053, Germany
Universitatsklinikum Frankfurt

Frankfurt, 60590, Germany
University of Alabama at Birmingham

Birmingham, Alabama, 35294-3300, United States
University of Maryland Medical Center

Baltimore, Maryland, 21201, United States
University of Mississippi Medical Center

Jackson, Mississippi, 39216, United States
Universitätsklinikum Gießen und Marburg GmbH Standort Gießen Medizinische Klinik I

Giessen, 35392, Germany
Universitätsspital Zürich

Zurich, 8091, Switzerland
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu

Wroc?aw, 50-367, Poland
Uniwersyteckie Centrum Kliniczne

Gdansk, 80-214, Poland
Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and Technology

Wuhan, 430022, China
Zhejiang Cancer Hospital

Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.